Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-35684-AAA-023: Size 1; small patch · 1 trial · 1 indication
Visual grading US FDA scale will be used to evaluate adhesion performance of the transdermal system. The score ranges from 0-4: 0 = greater than or equal to (\>=) 90 percent (%) adhered (essentially no lift off the skin); 1 = greater than or equal to 75% to less than (\<) 90% adhered (some edges only lifting off the skin); 2 = greater than or equal to 50% to \<75% adhered (less than half of the patch lifting off the skin); 3 = greater than (\>) 0% to \<50% adhered but not detached (more than half of the patch lifting off the skin without falling off); and 4 = 0% adhered - patch detached (patch completely off the skin).
Digital image will be captured with high resolution for each transdermal patch site and adhesion area will be calculated.
Total adhesion score will be calculated by visual grading grid system (a grid system based on 20 four-sided divisions that are approximately 5% of the total patch area; 44 cm\^2 patch will be evaluated by square and rectangular grid elements while 5.5 cm\^2 patch will be evaluated by square grid element only) which also contains a scale to allow for proper determination of actual area of the patch not adhering to the skin. Total area of the patch which does not adhere will be calculated. Any area of the patch that does not entirely adhere onto the skin will be scored as 0% adhesion for that area. Subsequently, a total adhesion score for that system will be calculated.
| Arm | Type | Description |
|---|---|---|
| JNJ-35684-AAA-023: 5.5 cm^2 Patch | EXPERIMENTAL | - |
| JNJ-35684-AAA-023: 44 cm^2 Patch | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JNJ-35684-AAA-023: Size 1; small patch | DRUG | Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm\^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours. |
| JNJ-35684-AAA-023: Size 2; large patch | DRUG | Placebo (matched to Fentanyl transdermal delivery device system \[TDDS\]) JNJ-35685-AAA-G-023 TDDS, 44 cm\^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours. |
Inclusion Criteria: * Body mass index (BMI: weight in kilogram \[kg\]/height\^2 \[meter (m\^2)\]) between 18 and 35 kg/m\^2 (inclusive), and body weight not less than 50 kg * Blood pressure (can be taken in supine or sitting position) between 90 and 140 milimeter of mercury (mmHg) systolic, inclusi...
JNJ-35684-AAA-023 is an investigational small molecule developed by Johnson & Johnson as a transdermal patch system. It is described as a size 1 small patch. The program is in Phase 1 clinical development, and the specific therapeutic indication has not been disclosed.
JNJ-35684-AAA-023 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the clinical study conducted for this patch system.
JNJ-35684-AAA-023 is in Phase 1 development. It is an investigational product and is not approved for any use. One early Phase 1 trial has been completed, and no trials are currently active.
JNJ-35684-AAA-023 has been evaluated in one completed early Phase 1 trial, NCT02221726, titled a study to assess adhesion quality and wear of a placebo transdermal system in healthy adults. The trial enrolled 16 male participants aged 18 years and older in the United States.
The completed trial NCT02221726 assessed adhesion quality and wear of the transdermal system in healthy adult male volunteers. It was a controlled, randomized study with 16 participants conducted in the United States. The patch tested in that trial was a placebo formulation.